Media Relations News Releases Year: - Any -20202019201820172016 Items per page 102550 Jun 8, 2016 Summary ToggleNovartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016 Jun 4, 2016 Summary ToggleNovartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna® Jun 1, 2016 Summary ToggleExpanding access to affordable treatments against chronic diseases – Novartis Access hosts second stakeholder dialogue May 17, 2016 Summary ToggleNovartis Foundation and partners launch innovative hypertension program in Vietnam May 15, 2016 Summary ToggleMajor study published in NEJM confirms Novartis’ Ultibro® Breezhaler® superiority over Seretide® in preventing COPD exacerbations Apr 27, 2016 Summary ToggleNovartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes Apr 2, 2016 Summary ToggleNew analyses show Novartis’ EntrestoTM reduced cardiovascular death or hospitalization forheart failure, consistently benefitting patients with reduced ejection fractionregardless of prior heart failure hospital admissions or background therapy Mar 5, 2016 Summary ToggleNovartis’ Cosentyx superior to Stelara in delivering long-lasting skin clearance (PASI 90) for psoriasis patients at 52 weeks Feb 26, 2016 Summary ToggleFDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET) Jan 31, 2016 Summary ToggleNovartis Foundation commemorates World Leprosy Day with its continued efforts to go the last mile toward elimination Pagination First page First Previous page Previous … Page 9 Page 10 Current page 11 Page 12 Next page Next Last page Last
